These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8549736)

  • 21. Noise exposure and hypertension: investigation of a silent relationship.
    de Souza TC; Périssé AR; Moura M
    BMC Public Health; 2015 Apr; 15():328. PubMed ID: 25880499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment.
    Muiesan ML; Salvetti M; Rizzoni D; Castellano M; Donato F; Agabiti-Rosei E
    J Hypertens; 1995 Oct; 13(10):1091-5. PubMed ID: 8586800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of left ventricular hypertrophy in a hypertensive population.
    Tingleff J; Munch M; Jakobsen TJ; Torp-Pedersen C; Olsen ME; Jensen KH; Jørgensen T; Kirchoff M
    Eur Heart J; 1996 Jan; 17(1):143-9. PubMed ID: 8682120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
    Ketelhut S; Franz IW; Ketelhut RG
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):385-390. PubMed ID: 30341642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and correlates of echocardiographic determined left ventricular hypertrophy in 2318 asymptomatic middle-aged men: the ECCIS project. Epidemiolgia e Clinica della Cardiopatia Ischemica Silente.
    Antoniucci D; Seccareccia F; Menotti A; Dovellini EV; Prati PL; Rovelli F; Fazzini PF
    G Ital Cardiol; 1997 Apr; 27(4):363-9. PubMed ID: 9199953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Left ventricular hypertrophy in nondiabetic predialysis CKD.
    Paoletti E; Bellino D; Cassottana P; Rolla D; Cannella G
    Am J Kidney Dis; 2005 Aug; 46(2):320-7. PubMed ID: 16112052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
    Gerdts E; Roman MJ; Palmieri V; Wachtell K; Smith G; Nieminen MS; Dahlöf B; Devereux RB
    J Hum Hypertens; 2004 Jun; 18(6):417-22. PubMed ID: 15103312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ambulatory hypertensive patients treated by cardiologists in France.
    Blacher J; Peroz-Froz J; Huberman JP; Ferrini M; Jullien G; Guenoun M; Guedj-Meynier D
    Arch Cardiovasc Dis; 2013 Feb; 106(2):86-92. PubMed ID: 23527912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
    Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA).
    Liljedahl S; Kahan T; Lind L; Arnlöv J
    Echocardiography; 2009 Aug; 26(7):753-8. PubMed ID: 19486119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients.
    Muiesan ML; Salvetti M; Monteduro C; Bonzi B; Paini A; Viola S; Poisa P; Rizzoni D; Castellano M; Agabiti-Rosei E
    Hypertension; 2004 Apr; 43(4):731-8. PubMed ID: 15007041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention.
    De Nicola L; Minutolo R; Chiodini P; Zoccali C; Castellino P; Donadio C; Strippoli M; Casino F; Giannattasio M; Petrarulo F; Virgilio M; Laraia E; Di Iorio BR; Savica V; Conte G;
    Kidney Int; 2006 Feb; 69(3):538-45. PubMed ID: 16395261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension.
    Iaccarino G; Izzo R; Trimarco V; Cipolletta E; Lanni F; Sorriento D; Iovino GL; Rozza F; De Luca N; Priante O; Di Renzo G; Trimarco B
    Clin Pharmacol Ther; 2006 Dec; 80(6):633-45. PubMed ID: 17178264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence, awareness, treatment and control of hypertension in employees of factories of Northern Greece: the Naoussa study.
    Sarafidis PA; Lasaridis A; Gousopoulos S; Zebekakis P; Nikolaidis P; Tziolas I; Papoulidou F
    J Hum Hypertens; 2004 Sep; 18(9):623-9. PubMed ID: 15029221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relationship between noise and blood pressure in an airport environment].
    Hammoudi N; Aoudi S; Tizi M; Larbi K; Bougherbal R
    Ann Cardiol Angeiol (Paris); 2013 Jun; 62(3):166-71. PubMed ID: 23759732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of losartan on left ventricular mass: a three-year follow-up in elderly hypertensives with myocardial hypertrophy despite successful conventional antihypertensive treatment.
    Moroni C; Tolone S; Lopreiato F; Scrofani AR; Bossini A; Affricano C; Cassone R; Gaudio C
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1323-1328. PubMed ID: 28387895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial.
    Verdecchia P; Staessen JA; Angeli F; de Simone G; Achilli A; Ganau A; Mureddu G; Pede S; Maggioni AP; Lucci D; Reboldi G;
    Lancet; 2009 Aug; 374(9689):525-33. PubMed ID: 19683638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of cardiovascular risk factors among 28,000 employees.
    Scheerbaum M; Langenbach C; Scheerbaum P; Heidemann F; Rieß HC; Heigel H; Debus SE; Behrendt CA
    Vasa; 2017 May; 46(3):203-210. PubMed ID: 28156256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a screening program for hypertension in a community.
    Radice M; Alli C; Avanzini F; Di Tullio M; Guiducci D; Mariotti G; Taioli E
    Acta Cardiol; 1991; 46(2):207-13. PubMed ID: 2048368
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of QRS voltage correction by body mass index to improve electrocardiographic detection of left ventricular hypertrophy in patients with systemic hypertension.
    Angeli F; Verdecchia P; Iacobellis G; Reboldi G
    Am J Cardiol; 2014 Aug; 114(3):427-32. PubMed ID: 24934758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.